The Pharmacy Times® Hematology Resource Center is a comprehensive resource for clinical news and expert insights on the treatment of blood disorders, including blood and bone marrow cancers, leukemia, and myeloma.
July 31st 2025
Sanofi's SAR446523 receives orphan drug designation for relapsed/refractory multiple myeloma, enhancing treatment options and patient outcomes.
Chemotherapy Parity Laws Ignore the Important Question of Cost Versus Quality
November 12th 2014According to researchers, chemotherapy parity laws ignore the real question of cost versus quality. At the same time, these laws promote anticompetitive practices that affect community oncologists.
Read More
Triple Antinausea Therapy Benefits Patients with Multiple Myeloma During Induction Therapy
September 27th 2014In a recent phase III trial, a 3-medication regimen showed efficacy in reducing treatment-related nausea and vomiting in patients with multiple myeloma undergoing induction therapy before autologous stem cell transplant.
Read More